Creatine and Brain: What Science Proves About Memory and Cognition

Creatine Creapure® — 120 capsules

The world's leading patented creatine monohydrate, in a convenient format for daily use. Purity ≥ 99.99%, Kölner Liste® certified.

View Creapure® →

Creatine Powder — 300 g

Pure creatine monohydrate in powder form, with flexible dosing suited to vegetarian profiles and personalized protocols. Best value for money.

View the powder →

The brain accounts for only 2% of body weight yet consumes approximately 20% of total energy expenditure at rest. Like muscles, neurons useATP as their energy currency — and like muscles, they possess reserves of phosphocreatine. It is these reserves that supplementation can increase, particularly in situations where the brain's energy demand is high or natural reserves are low.

The brain is, proportionally, the most energy-intensive organ in the human body. To function — thinking, memorizing, processing information, managing emotions, maintaining consciousness — it requires a constant and massive flow ofATP (adenosine triphosphate), the molecule that transports energy in all living cells.

Neurons produce their ATP primarily from glucose and oxygen, via mitochondrial respiration. But this process, while highly efficient, has one limitation: it takes time. When intense neural activity occurs suddenly — a quick decision, a prolonged concentration effort, a complex mental calculation — neurons needimmediately available ATP.

The role of cerebral phosphocreatine

This is where phosphocreatine. Stored in neurons, it can donate its phosphate group to ADP to instantly regenerate ATP — in less than one second. This reserve acts as an energy buffer that absorbs peaks in cerebral demand, before mitochondrial production takes over.

When brain creatine stores are low (insufficient sleep, aging, a meat-poor diet, metabolic stress), this buffer becomes less effective. Mental fatigue, cognitive slowing, and memory difficulties can set in more quickly.

Why the brain absorbs creatine less efficiently than muscles

Unlike muscles, the brain is protected by the blood-brain barrier, a cellular structure that strictly filters what can pass from the blood into nerve tissue. Creatine crosses this barrier, but more slowly and with less efficiency than in skeletal muscle.

This is why the cognitive effects of creatine generally require 4 to 6 weeks of continuous supplementation before they become measurable — whereas muscular effects appear within 1 to 3 weeks. This kinetic difference also explains why individuals whose brain stores are lowest benefit most rapidly from supplementation: seniors, vegetarians, sleep-deprived individuals, and those under chronic metabolic stress.

This information, seemingly simple, is crucial in deciding whether supplementation is worth trying. If your brain stores are already well stocked (young adult, omnivore, well-rested), the additional effect of creatine on cognition will be modest. If they are low, the effect will be significantly more noticeable — which is exactly what meta-analyses confirm, as we will see in the following sections.

According to Xu et al. 2024 in Frontiers in Nutrition, a rigorous meta-analysis of 16 randomized controlled trials including 492 participants aged 20 to 76 years confirms a beneficial effect of creatine monohydrate on memory (SMD +0.31, 95% CI: 0.18–0.44), on attention span and on information processing speed. The certainty of evidence for memory is rated as moderate according to the GRADE assessment.

What the SMD +0.31 actually measures

The SMD (standardized mean difference) of +0.31 corresponds to a small to moderate effect according to statistical conventions (Cohen). In practical terms, this means that individuals supplemented with creatine score better on average on memory tests than placebo groups, but the improvement remains modest — not a dramatic leap.

This is an important distinction to keep in mind: creatine is not a miracle nootropic. It won't transform a "normal" brain into a genius brain. It delivers a measurable but moderate improvement, particularly useful for optimizing cognitive functions that are already working properly, or for supporting a brain whose energy reserves are running low.

The subgroups that benefit most

Xu 2024 conducted subgroup analyses that reveal where creatine makes the biggest difference:

Intervention duration: short vs. long term

An important finding from Xu 2024: no significant difference was observed between short-term interventions (less than 4 weeks) and long-term ones (≥ 4 weeks) for overall cognitive improvement. This means that the cognitive effects of creatine take hold relatively quickly — generally within the first few weeks — but do not continue to grow indefinitely with very prolonged supplementation.

In practical terms: if you notice no subjective effect after 4 to 6 weeks of supplementation at 3–5 g/day, it is unlikely that continuing the regimen for months will change the outcome on a cognitive level. It is better to assess whether your profile matches the responding subgroups (older adults, women, those with a medical condition, vegetarians) before continuing.

According to Gordji-Nejad et al. 2024 in Scientific Reports, a single high dose of 0.35 g/kg of creatine monohydrate (approximately 25 g for a 70 kg adult) administered during a period of 21 hours of sleep deprivation was shown to maintain cognitive performance and processing speed, as well as prevent the drop in cerebral pH and the degradation of high-energy phosphates. This is the first study to demonstrate a measurable acute effect of creatine on the human brain.

This study, published in Scientific Reports (Nature group) in February 2024, quickly went viral in the biohacking community and shifted the scientific perception of creatine as an acute cognitive tool, not merely as a chronic supplement.

Why this study is a game changer

Before Gordji-Nejad 2024, the scientific consensus was clear: creatine only acts on the brain after several weeks of continuous supplementation, as cerebral stores gradually build up across the blood-brain barrier. The idea of an acute effect (within a matter of hours) seemed physiologically implausible.

The hypothesis put forward by researchers from Jülich (Germany) was bold: extreme cerebral energy demand (prolonged sleep deprivation) combined with very high plasma concentrations (a single massive dose of 0.35 g/kg) could temporarily increase cerebral uptake of creatine beyond normal levels.

The results, measured using phosphorus and proton magnetic resonance spectroscopy (¹H-MRS and ³¹P-MRS — cutting-edge metabolic brain imaging techniques), confirmed this hypothesis: measurable changes in the PCr/Pi ratio (phosphocreatine to inorganic phosphate), maintenance of cerebral ATP, and prevention of pH decline. And most notably, cognitive tests showed measurable improvement in performance and processing speed.

Important limitations to be aware of

This study is groundbreaking yet preliminary. Several precautions should be taken before adopting it as a routine practice:

Practical implications

For the vast majority of users, the recommended approach remains chronic supplementation at 3-5 g/day, which progressively saturates brain reserves over 4 to 6 weeks. This is the strategy validated by all meta-analyses (Xu 2024, Prokopidis 2023), with an excellent safety profile.

For exceptional situations (emergency all-nighter, critical cognitive performance under sleep deprivation, exam or presentation after a bad night's sleep), the high single-dose strategy could potentially have some merit — but it still requires further studies before being widely recommended.

According to Prokopidis et al. 2023 in Nutrition Reviews, a systematic review of 10 randomized controlled trials (of which 8 were included in the meta-analysis) on memory in healthy adults shows a modest overall effect (SMD +0.29, 95% CI 0.04-0.53), but markedly different depending on age: SMD +0.88 in seniors aged 66-76 years (a "large" effect according to Cohen) and SMD +0.03 in young adults aged 11-31 years (non-significant). It is in cognitive senescence that creatine shows its most pronounced potential.

Why such a pronounced effect in seniors

The SMD +0.88 is, according to Cohen's statistical conventions, a large effect — of the same order of magnitude as what is observed with intensive cognitive interventions (intensive cognitive training, certain nootropic medications). Three biological mechanisms explain this unusual magnitude:

1. Natural decline in cerebral creatine stores with age. Brain phosphocreatine stores gradually decrease after age 60, partly due to reduced endogenous synthesis (the liver and kidneys produce less creatine) and less efficient cerebral uptake. Supplementation more effectively addresses a deficit than it optimizes an already saturated brain.

2. Decline in dietary intake. With age, meat consumption tends to decrease (dental problems, reduced appetite, medically restricted diets). Yet red meat is the primary dietary source of creatine — a 200 g raw steak contains approximately 0.6 to 1 g, but cooking converts 10 to 30% of it into creatinine (the inactive form). In practice, a cooked 200 g steak provides around 0.4 to 0.8 g of effective creatine. Omnivorous seniors often consume less dietary creatine than younger adults.

3. Relatively higher cerebral energy demand. With aging, brain metabolism becomes less efficient (reduced mitochondrial performance, low-grade chronic inflammation). Phosphocreatine, as a rapid energy reserve, becomes proportionally more valuable in compensating for this decline in mitochondrial efficiency.

Why no effect in young adults?

The SMD of +0.03 in young adults (non-significant) is equally telling. A healthy, omnivorous young adult who gets enough sleep typically has brain creatine stores already close to their maximum. Adding creatine cannot increase what is already saturated.

This is an important finding for setting realistic expectations: if you are a student or a young healthy professional, do not expect a dramatic cognitive effect from creatine. Your stores are likely already well topped up. Any effect, if it exists at all, will be marginal — except in specific situations (sleep deprivation, acute metabolic stress, strict vegetarianism).

Implications for seniors and their families

For adults aged 60 and over who are concerned about age-related cognitive decline, creatine becomes a reasonable supplement to consider, under several conditions:

First, it should be part of a comprehensive strategy that includes regular physical activity (the combination of creatine + resistance training maximizes both muscular and cognitive benefits), quality sleep, a balanced diet, and cognitive stimulation (reading, learning, social engagement). Creatine alone cannot compensate for an unhealthy lifestyle.

Second, it should be used at a standard dose (3–5 g/day) of creatine monohydrate, taken continuously, with no loading phase required. Creapure® is a particularly well-suited choice here: maximum purity (99.99%), raw material certified by the Kölner Liste®, German traceability. To discover other supplements that support brain and muscle aging, see the Anti-aging collection and the Brain • Cognition collection.

Finally, in the event of kidney disease, diabetes, or use of medications (particularly psychotropic drugs), a discussion with a physician is recommended before starting supplementation.

According to Sherpa et al. 2024 in European Neuropsychopharmacology, a randomized double-blind pilot trial involving 100 participants with depression (50 creatine + cognitive behavioral therapy, 50 placebo + cognitive behavioral therapy) shows a reduction significantly greater reduction in depressive symptoms in the creatine group after 8 weeks (mean difference -5.12 points on the PHQ-9 scale). Tolerability and safety comparable to placebo. Promising but preliminary data, to be confirmed by larger trials.

The link between brain metabolism and depression

Over the past fifteen years or so, several brain imaging studies (magnetic resonance spectroscopy) have revealed a cerebral energy deficit in certain forms of major depression: decreased PCr/Pi ratio in key regions such as the prefrontal cortex and hippocampus, and mitochondrial metabolism abnormalities. This metabolic avenue has driven the hypothesis that creatine, by improving cerebral energy availability, could have a complementary antidepressant effect.

The Sherpa 2024 study, conducted as part of a partnership between the University of Oxford and a mental health center in northern India, rigorously tested this hypothesis: a randomized, double-blind, placebo-controlled trial, carried out in a resource-limited area where access to antidepressants remains difficult.

Conditions to be observed

According to Attia et al. 2017 in CNS & Neurological Disorders Drug Targets, a rigorous meta-analysis of 3 randomized controlled trials including 1,935 patients with Parkinson's disease shows NO beneficial effect of creatine on disease progression (total UPDRS scale and sub-scores I, II, III). This information is essential to avoid creating false hope: creatine supports healthy cognition, it does not treat established neurodegenerative diseases.

Why include this section in an article promoting creatine?

Because scientific integrity requires presenting all the data, including data that contradicts the expected effect. Much of the online content about creatine and the brain presents only positive studies, creating an illusion of omnipotence that ultimately does a disservice to the consumer.

The story of creatine and Parkinson's disease is instructive. In the early 2000s, preclinical studies (on cells and animals) had suggested that creatine might be neuroprotective against the dopaminergic degeneration characteristic of Parkinson's disease. The NIH (National Institute of Neurological Disorders and Stroke) had even selected creatine as a serious candidate for a large-scale clinical trial on disease modification.

The results of these rigorous clinical trials were negative. Across 1,935 patients followed in 3 large randomized controlled trials, no improvement on the UPDRS scale (Unified Parkinson's Disease Rating Scale, the reference scale for measuring disease progression) was observed vs placebo, neither on the total score nor on the motor sub-score (UPDRS III), daily activities (UPDRS II), or mental state (UPDRS I).

The lesson to be learned

Preclinical effects (cells, animals) do not systematically translate into clinical effects in humans. This is a general rule in pharmacology: the majority of promising laboratory candidates fail to demonstrate measurable clinical benefit.

Practical implication: if you take creatine to support your daily cognition, this is a reasonable strategy based on moderate evidence (Xu 2024, Prokopidis 2023, Gordji-Nejad 2024). If you are hoping it will slow a diagnosed neurodegenerative disease, current evidence does not support this use. For Alzheimer's and other dementias, the data remains at the preclinical stage and does not allow for any clinical conclusions to be drawn.

This does not mean that creatine should be ruled out in cases of neurodegenerative disease — its safety profile remains excellent and it may support muscle function, which often deteriorates in parallel (sarcopenia associated with Parkinson's disease, for example). But it should be taken without expecting any curative effect, in agreement with the medical team, and as part of a comprehensive approach.

According to Conti et al. 2024 in Nutrients, a comprehensive narrative review on nutritional protocols following traumatic brain injury (TBI) and concussion, creatine monohydrate and omega-3 fatty acids (EPA/DHA) are the two best-documented nutrients for reducing neuronal inflammation, limiting cellular damage and maintaining cerebral energy supply following trauma. This synergy is particularly relevant for contact sport athletes (rugby, American football, MMA, boxing, hockey).

The mechanisms of neuroprotection

A brain injury, even a mild one (concussion), triggers a precise biological cascade in the hours and days that follow: a sudden drop in neuronal ATP, increased oxidative stress, release of excitatory neurotransmitters in excess (glutamate), neuronal inflammation. It is this cascade — known as "metabolic mismatch" — that causes a large proportion of medium-term cognitive consequences (headaches, difficulty concentrating, persistent mental fatigue).

Creatine acts on two levels: it maintains neuronal ATP via the phosphocreatine buffer and it reduces excitatory glutamate release according to preclinical models. Omega-3 EPA/DHA, in turn, modulate neuronal inflammation through their resolving metabolites (resolvins, protectins, maresins). The combination of the two appears synergistic: energetic + anti-inflammatory.

Who is this synergy relevant for?

Conti 2024 focuses on individuals at high risk of concussion and traumatic brain injury, as well as individuals who have already experienced a TBI. In the medical literature, these at-risk populations classically include contact sport athletes (rugby, American football, MMA, hockey, boxing), military personnel exposed to repeated impacts, and victims of recent head trauma. For these populations, preventive or recovery-focused supplementation with creatine 3–5 g/day + omega-3 EPA/DHA 2–3 g/day is among the emerging nutritional protocols evaluated in the review.

For athletes not exposed to impacts (running, cycling, swimming, fitness), this synergy remains relevant for a different reason: it supports both muscular performance (creatine) and general anti-inflammatory recovery (omega-3). To explore this synergy, see our Omega-3 OmegaVie® EPA/DHA and the supplements from the Energy and Performance collection.

Dosage validated by all meta-analyses: 3 to 5 g/day of creatine monohydrate, continuously, taken every day for a minimum of 4 to 6 weeks to assess the cognitive effect. For seniors, vegetarians, and individuals with chronic sleep deprivation: more pronounced effects are expected. Documented brain synergies: omega-3 EPA/DHA (neuroinflammation), magnesium bisglycinate (sleep and synaptic function), Lion's Mane (BDNF, neuroplasticity), ashwagandha (cortisol and sleep quality).

Standard dosage

Dose: 3 to 5 g of creatine monohydrate per day. The same dose as for muscular effects. The loading phase (20 g/day × 5–7 days) is not necessary for cognitive effects and does not significantly accelerate brain benefits.

Form: creatine monohydrate exclusively, ideally Creapure® (capsules) for maximum purity or monohydrate powder for dosing flexibility and the best quantity/price ratio. Alternative forms (HCL, ethyl ester, Kre-Alkalyn®) provide no proven superior cognitive benefit.

Timing: irrelevant. Take with a meal to benefit from the insulin spike that promotes absorption, but exact timing has no significant impact on long-term cognitive benefits.

Duration: minimum 4 to 6 weeks to assess cognitive effect. Supplementation can be continued for years with no documented risk.

Validated brain synergies

Athletes and students

For a young student or cognitive worker, the effect of creatine remains modest if reserves are already saturated (omnivore, well-rested). The main benefit is to build a cerebral energy buffer for periods of intense cognitive stress (revision periods, deadlines, exams) — particularly when combined with insufficient sleep. Dose: 3-5 g/day, starting 4 weeks before the critical period.

For an athlete, creatine combines muscular benefits (strength, mass, recovery) and cognitive benefits (focus, decision-making, resistance to mental fatigue at the end of effort). It is the supplement that offers the best return on investment for this population. See the complete creatine guide for details on physical performance.

Self-test: can creatine help your brain?

Check the statements that apply to you. Based on the dominant profile that emerges, you will receive a personalized recommendation on the potential benefits of creatine for your cognition.

Personalized decision table

IF/THEN summary based on the 7 studies in this file — to help you decide quickly based on your profile.

FAQ — All your questions about creatine and the brain